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Abstract. 
 
We examined the activation of the p38 mito-
gen-activated protein kinase (p38-MAPK) pathway by 
the G protein–coupled receptor agonists, endothelin-1 
and phenylephrine in primary cultures of cardiac myo-
cytes from neonatal rat hearts. Both agonists increased 
the phosphorylation (activation) of p38-MAPK by 
 
z
 
12-fold. A p38-MAPK substrate, MAPK-activated 
protein kinase 2 (MAPKAPK2), was activated approxi-
mately fourfold and 10 
 
m
 
M SB203580, a p38-MAPK in-
hibitor, abolished this activation. Phosphorylation of 
the MAPKAPK2 substrate, heat shock protein 25/27, 
was also increased. Using selective inhibitors, activa-
tion of the p38-MAPK pathway by endothelin-1 was 
 
shown to involve protein kinase C but not G
 
i
 
/G
 
o
 
 nor 
the extracellularly responsive kinase (ERK) pathway. 
SB203580 failed to inhibit the morphological changes 
associated with cardiac myocyte hypertrophy induced 
by endothelin-1 or phenylephrine between 4 and 24 h. 
However, it decreased the myofibrillar organization 
and cell profile at 48 h. In contrast, inhibition of the 
ERK cascade with PD98059 prevented the increase in 
myofibrillar organization but not cell profile. These 
data are not consistent with a role for the p38-MAPK 
pathway in the immediate induction of the morphologi-
cal changes of hypertrophy but suggest that it may be 
necessary over a longer period to maintain the re-
sponse.
Key words: hypertrophy • cardioprotection • mitogen-
activated protein kinases • adrenergic agonists • endo-
thelin-1
 
T
 
he
 
 p38-MAPKs, extracellularly responsive kinases
(ERKs)
 
1
 
 and stress-activated protein kinases/c-Jun
NH
 
2
 
-terminal kinases (SAPKs/JNKs) constitute the
three best-characterized subgroups of the mitogen-acti-
vated protein kinase (MAPK) superfamily (reviewed by
Kyriakis and Avruch, 1996
 
a
 
, 1996
 
b
 
; Lee and Young, 1996;
Cohen, 1997). MAPKs are activated by the dual phosphor-
ylation of a Tyr and a Thr residue within a Thr-Xaa-Tyr
motif and the identity of Xaa assists in the classification of
subgroup membership. In the p38-MAPKs, Xaa is a Gly
residue. Several isoforms of p38-MAPKs have been char-
acterized. The original p38-MAPK (now sometimes called
p38-MAPK
 
a
 
; Han et al., 1993, 1994; Freshney et al., 1994;
Lee et al., 1994; Rouse et al., 1994; Zervos et al., 1995) ex-
ists as two alternatively spliced isoforms (Lee et al., 1994).
Subsequently, the 
 
b
 
1
 
/
 
b
 
2
 
 (Jiang et al., 1996; Kumar et al.,
1997), 
 
g
 
 (Li et al., 1996; Mertens et al., 1996), and 
 
d
 
 (Goe-
dert et al., 1997; Jiang et al., 1997) isoforms were identi-
fied. In many cells, p38-MAPKs are activated by a variety
of cellular stresses including inflammatory cytokines, endo-
toxins, UV irradiation and hyperosmotic shock (reviewed
by Lee and Young, 1996; Cohen, 1997). One substrate of
p38-MAPK
 
a
 
 and p38-MAPK
 
b
 
 is MAPK-activated pro-
tein kinase 2 (MAPKAPK2; Goedert et al., 1997; Kumar
et al., 1997), an enzyme that phosphorylates the small heat
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: ERK, extracellularly responsive ki-
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GPCR, G protein–coupled receptor; HSP, heat shock protein; MAPK, mi-
togen-activated protein kinase; MKK, MAPK kinase; MAPKAPK2,
MAPK-activated protein kinase 2; MEK, MAPK/ERK kinase; MBP, my-
elin basic protein; 
 
b
 
-MHC, 
 
b
 
-myosin heavy chain; PBS, Ca
 
2
 
1
 
/Mg
 
2
 
1
 
-free
Dulbecco’s phosphate-buffered saline; PE, phenylephrine; PTX, pertussis
toxin; SAPK/JNK, stress-activated protein kinase/c-Jun NH
 
2
 
-terminal ki-
nase.
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shock protein 25/27 (HSP25/27; Rouse et al., 1994). In un-
stressed cells, HSP25/27 exists predominantly in an un-
phosphorylated state as high molecular mass aggregates
(Lavoie et al., 1995). Phosphorylation leads to disaggrega-
tion (Lavoie et al., 1995) and is associated with protection
of the actin cytoskeleton (Guay et al., 1997; Huot et al.,
1997). Several other substrates of the p38-MAPK(s) have
been identified (reviewed by Cohen, 1997).
In the intact heart, p38-MAPK is activated by a variety
of stresses including ischemia and ischemia/reperfusion
(Bogoyevitch et al., 1996; Yin et al., 1997), oxidative stress
(Clerk et al., 1998), and hypertensive perfusion pressure
(Clerk et al., 1998). The biological functions of the p38-
MAPKs in the heart are not understood, although a recent
report using an inhibitor (SB203580; Lee et al., 1994;
Cuenda et al., 1995) that is selective for the 
 
a
 
 and 
 
b
 
1
 
 iso-
forms of p38-MAPK (Goedert et al., 1997; Kumar et al.,
1997) suggests that their activation may protect the heart
against ischemia (ischemic preconditioning; Weinbrenner
et al., 1997). p38-MAPK(s) has also been implicated in hy-
pertrophy of ventricular myocytes (Zechner et al., 1997).
This is an important adaptational response to a demand
for increased contractile power and is seen in a number of
clinical situations in man. Transient transfection of pri-
mary cultures of neonatal rat ventricular myocytes with an
expression plasmid encoding constitutively activated mu-
tants of MKK6 or MKK3 (the MAPK kinases (MKKs) re-
sponsible for the activation of p38-MAPK) induces the
transcriptional and morphological changes associated with
the development of the hypertrophic phenotype (Zechner
et al., 1997; Wang et al., 1998). SB203580 inhibited these
changes (Zechner et al., 1997). In addition, SB203580 in-
hibited the hypertrophic response induced by phenyleph-
rine (PE; Zechner et al., 1997), a powerfully hypertrophic
 
a
 
1
 
-adrenergic agonist (Simpson, 1985; Lee et al., 1988;
Iwaki et al., 1990; Knowlton et al., 1991).
G protein–coupled receptors (GPCRs) of the G
 
q/11
 
 class
participate in the cellular responses to 
 
a
 
1
 
-adrenergic ago-
nists such as PE and endothelin-1 (ET-1; reviewed by Sug-
den and Clerk, 1997). Like the 
 
a
 
1
 
-adrenergic agonists, ET-1
is powerfully hypertrophic (Shubeita et al., 1990; Ito et al.,
1991) and both 
 
a
 
1
 
-adrenergic agonism and ET-1 have
been implicated in ischemic preconditioning (Banerjee
et al., 1993; Wang et al., 1996). ET-1 and PE were first
shown to activate the ERKs in cardiac myocytes (Bogo-
yevitch et al., 1993, 1994; Clerk et al., 1994) and this was
the first MAPK cascade to be implicated in cardiac hyper-
trophy (Thorburn et al., 1994
 
a
 
; Gillespie-Brown et al.,
1995). Subsequently, SAPKs/JNKs were shown to be acti-
vated in cardiac myocytes by ET-1 and PE (Bogoyevitch
et al., 1995
 
a
 
; Ramirez et al., 1997), and these MAPKs have
also been implicated in cardiac hypertrophy (Bogoyevitch
et al., 1996; Ramirez et al., 1997). Although p38-MAPK
has been implicated in PE-induced hypertrophy, there are
only very limited data pertaining to the activation of p38-
MAPKs in cardiac myocytes by PE (Zechner et al., 1997)
and no data for ET-1 or other powerfully hypertrophic ag-
onists such as PMA.
Here, we have characterized extensively the activation of
the p38-MAPK pathway by the GPCR agonists, ET-1 and
PE, and compared these responses with those to hyper-
osmotic stress and PMA. We examined the phosphoryla-
 
tion of p38-MAPK, activation of its substrate MAPKAPK2,
and phosphorylation of HSP25/27 in primary cultures of
ventricular myocytes isolated from neonatal rat hearts. Us-
ing SB203580, we also assessed the role of the p38-MAPK
pathway in the development of the morphological changes
associated with the hypertrophic response.
 
Materials and Methods
 
Materials
 
Laminin, microcystin LR, myelin basic protein (MBP), pertussis toxin
(PTX), sorbitol, ET-1, PE, PMA, protein A–Sepharose and protease in-
hibitors were from Sigma Chemical Co. (Poole, Dorset, UK). PD98059
and GF109203X were from Calbiochem (Beeston, Nottinghamshire, UK)
and were prepared as 25 mM and 10 mM stock solutions in DMSO.
SB203580 was a gift from Dr. John C. Lee (SmithKline Beecham, King of
Prussia, PA) and a 10 mM stock solution was prepared in DMSO. Lab-
Tek tissue culture chamber slides were from Life Technologies (Paisley,
Scotland, UK). Other tissue culture materials were from previously de-
scribed sources (Bogoyevitch et al., 1995
 
b
 
). Prestained protein molecular
mass markers, ECL Western blotting reagents, autoradiography film and
streptavidi–Texas Red were from Amersham International (Amersham,
Buckinghamshire, UK). 
 
g
 
-[
 
32
 
P]ATP was from NEN Life Sciences (Brus-
sels, Belgium). SDS-PAGE reagents, IEF reagents, and Bradford (Brad-
ford, 1976) protein assay reagent were from Bio-Rad (Hemel Hempstead,
Hertfordshire, UK). Nitrocellulose was from Schleicher & Schuell and
supplied by Anderman & Co. (Kingston-upon-Thames, Surrey, UK).
cAMP-dependent protein kinase inhibitory peptide (sequence TTYAD-
FIASGRTGRRNAIHD) was from Bachem (Saffron Walden, Essex,
UK). The MAPKAPK2 substrate peptide (KKLNRTLSVA) was synthe-
sized by Severn Biotech (Kidderminster, Worcestershire, UK). The anti-
body to HSP25/27 (sc-1049) was from Santa Cruz Biotechnology Inc. and
supplied by Autogen Bioclear (Devizes, Wiltshire, UK). The antibody to
the dually phosphorylated form of p38-MAPK was from New England Bi-
olabs (UK) Ltd. (Hitchin, Herts., UK). A mouse monoclonal antibody to
 
b
 
-myosin heavy chain (
 
b
 
-MHC) was from Novocastra (Newcastle-upon-
Tyne, Tyne and Wear, UK). Secondary antibodies (horseradish peroxidase–
linked, FITC and biotinylated anti–mouse and anti–rabbit IgG antibodies)
and fluorescent mounting medium were from Dako (High Wycombe,
Buckinghamshire, UK).
 
Primary Culture of Neonatal Ventricular Myocytes and 
Sample Preparation
 
Myocytes were dissociated from the ventricles of neonatal Sprague-Daw-
ley rat hearts by a previously described adaptation (Bogoyevitch et al.,
1995
 
b
 
) of the method of Iwaki et al., (Iwaki et al., 1990). To deplete the
myocytes of fibroblasts, the cells were preplated in DMEM/M199 (4:1 vol/
vol) supplemented with 10% (vol/vol) horse serum, 5% (vol/vol) fetal calf
serum and 100 U/ml each of penicillin and streptomycin. The (nonadher-
ent) myocytes were then plated on 60- or 35-mm culture dishes precoated
with 1% (wt/vol) gelatin at a density of 1.4 
 
3
 
 10
 
3
 
 cells/mm
 
2
 
. Myocytes
were confluent and beating within 18 h. The cells were incubated for 24 h
in serum-free medium in the absence or presence (in some experiments)
of 1 
 
m
 
M PMA or 30 ng/ml PTX, and then exposed to agonists (0.5 M sor-
bitol, ET-1, PE or 1 
 
m
 
M PMA) in serum-free medium. For inhibitor stud-
ies, the cells were preincubated with inhibitor for 15 min before stimulation
with agonist 
 
1
 
 inhibitor. For phospho–p38-MAPK immunoblot analysis
and fast protein liquid chromatography (FPLC), myocytes (60-mm dishes)
were washed in ice-cold Ca
 
2
 
1
 
/Mg
 
2
 
1
 
-free Dulbecco’s phosphate-buffered
saline (PBS) and scraped into 150 
 
m
 
l/dish extraction buffer A (20 mM
 
b
 
-glycerophosphate, pH 7.5, 50 mM NaF, 2 
 
m
 
M microcystin LR, 2 mM
EDTA, 0.2 mM Na
 
3
 
VO
 
4
 
, 10 mM benzamidine, 200 
 
m
 
M leupeptin, 10 
 
m
 
M
trans-epoxy succinyl-
 
L
 
-leucylamido-(4-guanidino)butane, 5 mM DTT, 300
 
m
 
M PMSF, 1% (vol/vol) Triton X-100). The samples were centrifuged
(10,000 
 
g
 
, 5 min, 4
 
8
 
C). For Western blotting, supernatants were boiled
with 0.33 vol of sample buffer (0.33 M Tris-HCl pH 6.8, 10% (wt/vol)
SDS, 13% (vol/vol) glycerol, 133 mM DTT, 0.2 mg/ml bromophenol blue).
For FPLC, supernatants were re-centrifuged (10,000 
 
g
 
, 5 min, 4
 
8
 
C) before
loading onto the column. Protein concentrations were determined using
the Bradford method (Bradford, 1976). 
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Phospho-p38-MAPK Immunoblot Analysis
 
Myocyte extracts (25 
 
m
 
g protein) were immunoblotted for phospho-p38-
MAPK according to the manufacturer’s instructions. The bands were de-
tected using enhanced chemiluminescence (ECL) with exposure to Hy-
perfilm MP. Blots were quantified by laser scanning densitometry.
 
Fast Protein Liquid Chromatography (FPLC) of ERKs 
and MAPKAPK2
 
ERKs (four 60-mm dishes/column) were separated on a Mono Q HR5/5
column equilibrated with 50 mM Tris-HCl, pH 7.3, 2 mM EDTA, 2 mM
EGTA, 0.1% (vol/vol) 2-mercaptoethanol, 5% (vol/vol) glycerol, 0.03%
(vol/vol) Brij-35, 0.3 mM Na
 
3
 
VO
 
4
 
, 1 mM benzamidine, and 4 
 
m
 
g/ml leu-
peptin. After a 5-ml isocratic wash, ERKs were eluted using a linear NaCl
gradient (20 ml, 0–0.33 M NaCl) at a flow rate of 1 ml/min with collection
of 0.5-ml fractions. They were assayed by the incorporation of 
 
32
 
P from
 
g
 
-[
 
32
 
P]ATP into MBP by the direct method as previously described (Bogo-
yevitch et al., 1993, 1994), except that in some experiments the assay mix in-
cluded 0.1% (vol/vol) DMSO or 10 
 
m
 
M SB203580 (final concentrations).
MAPKAPK2 (two 60-mm dishes/column) was partially purified by
FPLC on a Mono S HR5/5 column equilibrated with 25 mM 
 
b
 
-glycero-
phosphate pH 7.3, 2 mM EDTA, 5% (vol/vol) glycerol, 0.1% (vol/vol)
Triton X-100 and 0.5 mM DTT. After a 5-ml isocratic wash, MAPKAPK2
was eluted using a linear NaCl gradient (15 ml, 0–0.3 M NaCl) at a flow
rate of 1 ml/min with collection of 1 ml fractions. MAPKAPK2 was as-
sayed by the incorporation of 
 
32
 
P from 
 
g
 
-[
 
32
 
P]ATP into KKLNRTLSVA
peptide substrate (Rouse et al., 1994) as previously described (Bogo-
yevitch et al., 1996), except that the incubation time was decreased to 20
min. Total MAPKAPK2 activities were determined by integration of the
areas under the FPLC peaks.
 
Isoelectric Focusing (IEF) and Immunoblotting
of HSP25/27
 
Myocytes (in 35-mm dishes) were scraped into 100 
 
m
 
l/dish of extraction
buffer B (12.5 mM Tris-HCl, pH 7.5, 2.5 mM EGTA, 1 mM EDTA, 100 mM
NaF, 5 mM DTT, 0.3 mM PMSF, 0.12 mM pepstatin A, 0.2 mM leupeptin,
10 
 
m
 
M trans-epoxy succinyl-
 
L
 
-leucylamido-(4-guanidino)butane), and cen-
trifuged (10,000 
 
g
 
, 5 min, 4
 
8
 
C). Supernatants were mixed with an equal vol-
ume of 8 M urea, 4% (wt/vol) Biolyte 3-10, 1% (vol/vol) Triton X-100. Sam-
ples (2 
 
m
 
l, 2–3 
 
m
 
g protein) were separated by IEF on 5% polyacrylamide gels
containing 4 M urea, 0.2% (wt/vol) CHAPS, 5% (vol/vol) glycerol, 2% (wt/
vol) Biolyte 3-10 at 100 V (15 min), and finally 450 V (1 h). Proteins were
transferred to nitrocellulose and probed with HSP25/27 antibodies (1/100
dilution). Blots were processed as previously described (Clerk et al., 1994).
 
Immunocytochemical Staining
 
Cells were plated in 8-well Lab-Tek tissue culture chamber slides pre-
coated with laminin (20 
 
m
 
g/ml in PBS) and 1% (wt/vol) gelatin at a density
of 5 
 
3
 
 10
 
4
 
 cells/well (
 
z
 
600 cells/mm
 
2
 
) and cultured for 18 h. Serum was
withdrawn for 24 h before the experiments. Cells were pretreated (15 min)
with 0.1% (vol/vol) DMSO or inhibitors and then left unstimulated or ex-
posed to agonists in serum-free medium containing 0.1% (vol/vol) DMSO
or inhibitors. After 4, 8, 24, or 48 h, the medium was removed and the cells
washed with ice-cold PBS (3 
 
3
 
 0.5 ml). The cells were fixed for 10 min with
4% (wt/vol) formaldehyde, permeabilized with 0.3% (vol/vol) Triton
X-100 in PBS and nonspecific antibody binding blocked with 1% (wt/vol)
BSA in PBS containing 0.3% (vol/vol) Triton X-100. The cells were immu-
nostained with an antibody to 
 
b
 
-MHC (1/40 dilution, 1 h, 37
 
8
 
C), using a
biotinylated anti–mouse IgG secondary antibody (1/200 dilution, 30 min,
37
 
8
 
C) and streptavidin–Texas Red (1/200 dilution, 15 min, 37
 
8
 
C). All anti-
body dilutions were in PBS and wells were washed with PBS (3 
 
3
 
 0.5 ml)
between each incubation. Slides were mounted and examined using a Zeiss
Axioskop microscope with a 100
 
3
 
 oil immersion objective. Cells were
photographed using Tmax 400 film with a set exposure time (30 s).
 
Results
 
Phosphorylation of p38-MAPK
 
To assess the activation of p38-MAPK in cardiac myocytes,
we used an antibody selective for the dually phosphory-
lated (activated) form of the p38-MAPKs for Western blot
analysis. Hyperosmotic shock (0.5 M sorbitol) stimulated
extensive phosphorylation of p38-MAPK (
 
z
 
25-fold rela-
tive to controls; Fig. 1 
 
A
 
, 
 
top
 
). This response was rapid and
maximal within 5 min (Fig. 1 
 
B
 
). ET-1 (100 nM) and PE
(100 
 
m
 
M) also stimulated a rapid but less extensive phos-
phorylation of p38-MAPK (
 
z
 
12-fold) which was sustained
up to at least 20 min (Fig. 1 
 
A
 
, 
 
center 
 
and 
 
B
 
). The phos-
phorylation of p38-MAPK in response to PMA (1 
 
m
 
M)
was rapid but was considerably less than with the other ag-
onists (Fig. 1 
 
A
 
, 
 
lower
 
 and 
 
B
 
). We directly compared the
relative phosphorylation of p38-MAPK induced by the
four agonists after 5 min (Fig. 2, 
 
A
 
 and 
 
B
 
). Taking the re-
sponse to 0.5 M sorbitol as 100%, the relative levels of
Figure 1. Phosphorylation of p38-MAPK by sorbitol, ET-1, PE,
and PMA. Myocytes were exposed to 0.5 M sorbitol, 100 nM ET-1,
100 mM PE, or 1 mM PMA for the times indicated. (A) Extracts
were immunoblotted for phosphorylated p38-MAPK as de-
scribed in Materials and Methods. Arrows indicate phosphory-
lated p38-MAPK. Blots are representative of three independent
experiments. (B) Immunoblotted phosphorylated p38-MAPK
from myocytes exposed to sorbitol (d, solid line), ET-1 (j, solid
line), PE (m, dashed line), or PMA (s, dotted line) was quantified
by laser scanning densitometry. Results are means 6 SEM for
three independent experiments.The Journal of Cell Biology, Volume 142, 1998 526
phosphorylation induced by ET-1 (100 nM), PE (100 mM),
and PMA (1 mM) were 52, 40, and 13%, respectively.
The EC50 for stimulation of many biological processes
in cardiac myocytes by ET-1 is in the nM range (reviewed
by Rubanyi and Polokoff, 1994; Sugden and Bogoyevitch,
1996). Consistent with this, the EC50 for ET-1 stimulation
of p38-MAPK phosphorylation was 0.46 6 0.01 nM (mean 6
SEM of three independent experiments; Fig. 3, A and B).
In two independent experiments, the ETA receptor antag-
onist, BQ123 (10 mM, 15 min pretreatment), inhibited the
phosphorylation of p38-MAPK induced by ET-1 (100 nM,
5 min) as assessed by immunoblotting (results not shown).
Quantitative analysis by laser scanning densitometry indi-
cated that this inhibition was 71 6 17% (mean 6 SD).
Activation of MAPKAPK2
MAPKAPK2 is a substrate for p38-MAPK (Rouse et al.,
1994). In addition to being an important effector in its own
right, the stimulation of MAPKAPK2 is a useful indication
of p38-MAPK activation. We measured MAPKAPK2 ac-
tivity in cardiac myocytes after partial purification by Mono
S FPLC. Sorbitol (0.5 M) stimulated a very rapid increase in
MAPKAPK2 activity that was essentially complete within
5 min and was sustained for up to 30 min (Fig. 4 A). ET-1
(100 nM), PE (100 mM), and PMA (1 mM) stimulated modest
but sustained increases in MAPKAPK2 activity (Fig. 4 A).
The potency of these agonists was compared after 30 min
incubation (Fig. 4 B). Sorbitol stimulated an 8.6-fold in-
crease over control values, whereas the stimulation by ET-1,
PE and PMA were 5.0-, 3.9-, and 2.8-fold, respectively.
Consistent with activation of MAPKAPK2 by p38-MAPK,
SB203580, a selective inhibitor of p38-MAPK/p38-MAPKb
(Goedert et al., 1997; Kumar et al., 1997), essentially com-
pletely inhibited the activation of MAPKAPK2 by all four
agonists (Fig. 4 B).
MAPKAPK2 was initially identified as a substrate for
the ERKs (Stokoe et al., 1992), which are strongly acti-
vated in cardiac myocytes by PMA, ET-1 and PE (Bogoy-
evitch et al., 1993, 1994; Clerk et al., 1994). To confirm that
ERKs are not inhibited by SB203580 and the inhibition of
MAPKAPK2 activity by this drug reflects its inhibitory
effects on p38-MAPK, we purified ERK1 and ERK2 by
Mono Q FPLC from myocytes exposed to PMA (1 mM,
5 min) and assayed activity in the presence of 0.1% (vol/vol)
DMSO or 10 mM SB203580. There was no inhibition of
either ERK1 or ERK2 by SB203580 (Fig. 4 C), indicating
that p38-MAPK activity is essential for MAPKAPK2 acti-
vation in neonatal ventricular myocytes.
Mechanisms of Activation of the p38-MAPK Pathway
Inhibition by PTX. ET-1, in addition to stimulating Gq/11-
dependent pathways, also couples to Gi in cardiac myo-
cytes (Hilal-Dandan et al., 1994). We investigated the
potential involvement of Gi in the activation of the p38-
MAPK pathway. Pretreatment of myocytes with 30 ng/ml
PTX for 24 h had no effect on the basal levels of phosphor-
ylated p38-MAPK, or on the phosphorylation of p38-
MAPK induced by 100 nM ET-1 (Fig. 5 A) or 0.5 M sorbi-
tol (Fig. 5 B). Similarly, neither the basal levels of
MAPKAPK2 activity nor the activation of MAPKAPK2
by ET-1 (Fig. 5 C) or sorbitol (Fig. 5 D) was affected by
PTX pretreatment. In separate experiments, this regime
Figure 2. Direct comparison of the degree of p38-MAPK phos-
phorylation induced by sorbitol, ET-1, PE, and PMA. Myocytes
were unstimulated (C) or exposed to 0.5 M sorbitol (S), 100 nM
ET-1, 100 mM PE, or 1 mM PMA for 5 min. (A) Extracts were im-
munoblotted for phosphorylated p38-MAPK as described in the
Materials and Methods. The blot is representative of three inde-
pendent experiments. (B) Immunoblotted phosphorylated p38-
MAPK was quantified by laser scanning densitometry. Results
are means 6 SEM for three independent experiments.
Figure 3. Concentration-dependent phosphorylation of p38-
MAPK by ET-1. Myocytes were exposed to the indicated concen-
trations of ET-1 for 5 min. (A) Extracts were immunoblotted for
phosphorylated p38-MAPK as described in Materials and Meth-
ods. The blot is representative of three independent experiments.
(B) Immunoblotted phosphorylated p38-MAPK was quantified
by laser scanning densitometry. Results are means 6 SEM for
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of PTX pretreatment inhibited Raf activation by ET-1
(Chiloeches, A., and P.H. Sugden, unpublished observa-
tions) indicating the efficacy of this protocol. These data
demonstrate that ET-1 stimulation of the p38-MAPK
pathway is not mediated through PTX-sensitive G pro-
teins (i.e., Gi or Go).
Involvement of PKC. Preexposure of myocytes to 1 mM
PMA for 24 h essentially completely downregulates the
classical and novel PKC isoforms (Clerk et al., 1995). This
protocol increased the basal levels of phosphorylated p38-
MAPK (Fig. 5 A) and MAPKAPK2 activity (Fig. 5 C) by
two- to threefold. Phosphorylation of p38-MAPK induced
by 100 nM ET-1 was inhibited by PMA pretreatment (Fig.
5 A). To evaluate the degree of inhibition, the basal levels
of phosphorylated p38-MAPK or MAPKAPK2 activity
were subtracted from values obtained in the presence of
agonist. The inhibition of ET-1 stimulated p38-MAPK
phosphorylation by PMA pretreatment was 79 6 8%
(mean 6 SEM for three independent experiments). In
contrast, the phosphorylation of p38-MAPK by 0.5 M sor-
bitol was not inhibited by PMA pretreatment (Fig. 5 B).
Activation of MAPKAPK2 by ET-1 was inhibited (47 6
7%, mean 6 SEM for four independent experiments) by
PMA pretreatment (Fig. 5 C), whereas the activation of
MAPKAPK2 by sorbitol was unaffected (Fig. 5 D).
We also assessed the effects of a PKC-selective inhibi-
tor, GF109203X (Toullec et al., 1991). This is a more se-
lective PKC inhibitor than staurosporine and, unlike
Ro318220 (Beltman et al., 1996), does not strongly acti-
vate the SAPKs/JNKs in cardiac myocytes (Clerk, A., and
P.H. Sugden, unpublished observations). GF109203X (10
mM) increased the basal levels of phosphorylated p38-
MAPK (Fig. 5 A), although there was no effect on basal
MAPKAPK2 activity (Fig. 5 B). GF109203X (10 mM) had
no effect on the phosphorylation of p38-MAPK (Fig. 5 B)
or the activation of MAPKAPK2 (Fig. 5 D) by sorbitol,
but inhibited the ET-1–stimulated phosphorylation of p38-
MAPK (Fig. 5 A) and activation of MAPKAPK2 (Fig. 5 C)
by 63 6 8% and 64 6 7%, respectively (means 6 SEM for
three or four independent experiments). A lower concentra-
tion of GF109203X (1 mM) had no effect on ET-1 stimula-
tion of either p38-MAPK phosphorylation or MAPKAPK2
activation (results not shown). Published IC50 values for
inhibition of partially purified PKC by GF109203X are
z10 nM (Toullec et al., 1991), considerably less than we
observed here. Therefore, using Mono Q FPLC to sepa-
rate the MAPKs, we assessed the effects of GF109203X on
the activation of ERKs in cardiac myocytes by ET-1, a re-
sponse that is accepted to be predominantly PKC-depen-
dent (Bogoyevitch et al., 1994). ET-1 stimulated two peaks
of activity eluting at z0.20 M and 0.25 M NaCl (ERK2 and
ERK1, respectively; Fig. 6 A). At 1 mM, GF109203X had
no effect on the activation of ERK2, but inhibited the acti-
vation of ERK1 by z30% (Fig. 6 B). At 10 mM, activation
of both ERK1 and ERK2 were significantly inhibited (Fig.
6 B). This indicates that the IC50 for the inhibition of PKC-
dependent processes by GF109203X in cardiac myocytes is
considerably greater than for purified PKC.
Involvement of the ERK Cascade. PD98059 inhibits the
activation of MEK1 and, to a lesser extent, MEK2 (Alessi
et al., 1995; Dudley et al., 1995), both of which are in-
volved in ERK activation. We examined the effect of this
Figure 4. p38-MAPK dependent activation of MAPKAPK2 by
sorbitol, ET-1, PE and PMA. (A) Myocytes were exposed to 0.5 M
sorbitol (d, solid line), 100 nM ET-1 (j, solid line), 100 mM PE
(m, dashed line), or 1 mM PMA (s, dotted line) for the times indi-
cated. MAPKAPK2 activities were measured as described in Ma-
terials and Methods. Results are means 6 SEM for three inde-
pendent experiments. No increase in MAPKAPK2 activity was
detected in unstimulated cells over this time (results not shown).
(B) Myocytes were exposed to 0.5 M sorbitol (S), 100 nM ET-1,
100 mM PE, or 1 mM PMA for 5 min in the presence of 0.1% (vol/
vol) DMSO (solid bars) or 10 mM SB203580 (hatched bars).
MAPKAPK2 activities were measured as described in Materials
and Methods. Results are means 6 SEM for three independent
experiments. (C) Myocytes were exposed to 1 mM PMA for 5 min
and ERK activities were separated on Mono Q FPLC and as-
sayed in the presence of 0.1% (vol/vol) DMSO (d, solid line) or
10 mM SB203580 (m, dashed line) as described in Materials and
Methods. The NaCl gradient is shown by the dotted line.The Journal of Cell Biology, Volume 142, 1998 528
drug on the activation of the p38-MAPK pathway to de-
termine whether the same MKKs are involved in the acti-
vation of ERKs and p38-MAPK in cardiac myocytes.
PD98059 (50 mM) increased basal levels of phosphory-
lated p38-MAPK (Fig. 5 A) and MAPKAPK2 activity
(Fig. 5 C). The phosphorylation of p38-MAPK and activa-
tion of MAPKAPK2 induced by 0.5 M sorbitol were unaf-
fected by 50 mM PD98059 (Fig. 5, B and D). In contrast,
50 mM PD98059 inhibited the ET-1 (100 nM) stimulated
phosphorylation of p38-MAPK (Fig. 5 A) and activation
of MAPKAPK2 (Fig. 5 C) by 50 6 3% and 67 6 3%
(means 6 SEM for four independent experiments), re-
spectively. In two separate experiments, a lower concen-
tration of PD98059 (10 mM) gave no significant inhibition
of MAPKAPK2 activation by ET-1 (results not shown).
However, the activation of ERK1 and ERK2 by ET-1 was
significantly inhibited (.80%) by 10 mM or 50 mM
PD98059 (Fig. 6 C). These data indicate that although
both ERKs and p38-MAPK may be similarly PKC depen-
dent, the pathways diverge at a level before the MKKs.
The results also suggest that whereas ERK activation is
probably mediated through MEK1 in these cells (the IC50
for MEK1 inhibition by PD98059 is 10 mM; Alessi et al.,
1995), activation of p38-MAPK may be mediated through
MEK2 (the IC50 for MEK2 inhibition is 50 mM; Alessi et
al., 1995) or another MKK which is sensitive to inhibition
by PD98059.
Phosphorylation of HSP25/27. In certain cell types, phos-
phorylation of HSP25/27 is associated with cytoprotection
and stabilization of the actin cytoskeleton (Guay et al.,
1997; Huot et al., 1997). HSP25/27 is a known substrate for
MAPKAPK2 (Rouse et al., 1994). Therefore, we assessed
the phosphorylation state of HSP25/27 in cells exposed to
100 nM ET-1 using IEF followed by immunoblotting. An
increase in the phosphorylation of HSP25/27 increases the
negative charge of the protein that allows it to migrate
more quickly to the anode during the IEF stage. The indi-
vidual phosphorylated forms of HSP25/27 are then specifi-
cally identified by immunoblotting. Up to three forms of
HSP25/27 were detected using this method. In unstimu-
lated cells, HSP25/27 was detected predominantly as
bands 1 and 2, the most positively charged (least phosphor-
ylated) forms migrating closest to the cathode (Fig. 7, top).
In myocytes subjected to cellular stress (0.5 M sorbitol, 30
min), HSP25/27 was detected principally as bands 2 and 3,
the more negatively charged forms. ET-1 stimulated an in-
crease in the levels of band 3 from z5–8 min with a corre-
sponding decrease in the levels of band 1, indicating an in-
crease in the phosphorylation state of HSP25/27. This change
was maximal at z30 min, and was sustained at least up to
1 h. The increase in phosphorylation of HSP25/27 induced
by ET-1 was comparable to that induced by 0.5 M sorbitol.
SB203580 completely inhibited this response (results not
shown), consistent with the stimulation of HSP25/27 phos-
phorylation by ET-1 being mediated by p38-MAPK/
MAPKAPK2.
Effects of p38-MAPK Inhibition on Cardiac Myocyte Hy-
pertrophy/Cell Survival. We investigated the effects of p38-
MAPK inhibition on the morphological changes induced
in cardiac myocytes by ET-1 and PE over a period of 4–48 h.
We compared the effects of SB203580 with those of
PD98059, which inhibits the ERK cascade but also par-
tially inhibits the p38-MAPK pathway (Fig. 6 C). Myo-
cytes were cultured in chamber slides and either not stimu-
lated or exposed to agonists in the absence or presence of
inhibitors. The myofilaments were immunostained with an
antibody to b-MHC. Control cells, cultured in serum-free
medium for up to 24 h, were irregular and the myofila-
Figure 5. Effects of PTX, PKC inhi-
bition and PD98059 on phosphory-
lation of p38-MAPK and activation
of MAPKAPK2. Myocytes were ei-
ther not exposed to inhibitors
(CON) or pretreated with PTX (30
ng/ml, 24 h), PMA (1 mM, 24 h),
GF109203X (GF; 10 mM, 15 min) or
PD98059 (PD; 50 mM, 15 min).
They were then exposed to 100 nM
ET-1 for 5 min (solid bars), 0.5 M
sorbitol for 5 min (cross-hatched
bars) or left unstimulated (open
bars) as described in Materials and
Methods. (A and B) Phosphoryla-
tion of p38-MAPK by ET-1 (A) or
sorbitol (B) was assessed by immu-
noblotting and laser scanning densi-
tometry as described in Materials
and Methods. (C and D) Activation
of MAPKAPK2 by ET-1 (C) or sor-
bitol (D) was measured as de-
scribed in Materials and Methods.
Results are means 6 SEMs for
three to nine independent experi-
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ments were disorganized (Figs. 8 A, 9 A, and 10 A). Myo-
cytes exposed to 50 mM PD98059 (e.g., Figs. 9 D and 10 D)
or SB203580 (e.g., Figs. 9 G and 10 G) appeared similar to
the control cells at all time points studied.
From as early as 4 h, 40 mM PE (Fig. 8 B) or 40 nM ET-1
(Fig. 8 C) stimulated an increase in cell profile and myo-
fibrillar organization relative to the controls (Fig. 8 A). By
8 h, cells exposed to either PE (Fig. 9 B) or ET-1 (Fig. 9 C)
exhibited the typical morphology associated with cardiac
hypertrophy. The cells were larger, with intense b-MHC
staining and clear cross-striations. In myocytes exposed to
either agonist in the presence of 50 mM PD98059, the myo-
fibrillar organization was disrupted although there was no
apparent decrease in the intensity of b-MHC immu-
nostaining (Fig. 9, E and F). In contrast, 10 mM SB203580
had no effect on the morphology of myocytes stimulated
with PE (Fig. 9 H) or ET-1 (Fig. 9 I).
After 24 h, control myocytes maintained in serum-free
medium appeared smaller than those at 4 or 8 h, with re-
duced b-MHC immunostaining (Fig. 10 A), whereas cells
exposed to PE (Fig. 10 B) or ET-1 (Fig. 10 C) exhibited
a similar morphology to those at 8 h (Fig. 9, B and C, res-
pectively). In myocytes exposed to either agonist in the pres-
ence of 50 mM PD98059 for 24 h, the myofibrillar orga-
nization was clearly disrupted although there was no
apparent decrease in the intensity of b-MHC immu-
nostaining or in cell profile (Fig. 9, E and F). SB203580
(10 mM) had no effect on any aspect of the morphological
changes induced in myocytes by PE (Fig. 10 H) or ET-1
(Fig. 10 I) after 24 h.
In addition to inhibiting ERK activation (Fig. 6), 50 mM
PD98059 also inhibits the activation of p38-MAPK and
MAPKAPK2 by ET-1 (Fig. 5). However, 10 mM PD98059
(which does not significantly inhibit MAPKAPK2 activa-
tion, but does inhibit ERK activation [Fig. 6]) also dis-
rupted the myofibrillar organization induced by ET-1 or
PE for 8 and 24 h (results not shown). Furthermore, 10 mM
SB203580 together with 10 mM (or 50 mM) PD98059 had
no additional effect on the morphology of myocytes ex-
posed to ET-1 or PE for 8 or 24 h (results not shown).
These results indicate that the effect of PD98059 to disrupt
myocyte myofibrillar organization is not attributable its in-
hibition of the p38-MAPK pathway.
After 48 h in serum-free medium, there were consider-
ably fewer myocytes in the control wells and there was a
substantial amount of cell debris (e.g., Fig. 11 A, arrow-
head). The remaining myocytes were small, with very little
b-MHC staining (Fig. 11 A). The number of myocytes in
wells treated with PE or ET-1 appeared similar to the
other time points studied (results not shown), suggesting
that agonist stimulation promotes survival of cardiac myo-
cytes. Myocytes exposed to PE for 48 h exhibited two pat-
terns of morphology. Approximately 50% of the cells were
large and clearly striated with very bright immunostaining
for b-MHC (Fig. 11 B). The remaining cells were weakly
stained for b-MHC, but were still striated (Fig. 11 C). Myo-
Figure 6. Inhibition of ET-1–stimulated ERK activation by
GF109203X and PD98059. (A) Myocytes were pretreated with
0.2% (vol/vol) DMSO for 15 min and either left unstimulated (s,
dashed line), or exposed to 100 nM ET-1 for 5 min (d, solid line).
ERKs were separated by Mono Q FPLC and assayed as de-
scribed in Materials and Methods. The NaCl gradient is shown by
the dotted line. The experiment was repeated with essentially
similar results. (B) Myocytes were pretreated with 0.2% (vol/vol)
DMSO (d, solid line), 1 mM GF109203X (m, dashed line), or 10 mM
GF109203X (j, solid line) for 15 min, and then exposed to 100 nM
ET-1 for 5 min. ERKs were separated by Mono Q FPLC and as-
sayed as described in Materials and Methods. The NaCl gradient
is shown by the dotted line. The experiment was repeated with
essentially similar results. (C) Myocytes were pretreated with
0.2% (vol/vol) DMSO (d, solid line), 10 mM PD98059 (m, dashed
line), or 50 mM PD98059 (j, solid line) for 15 min, and then ex-
posed to 100 nM ET-1 for 5 min. ERKs were separated by Mono
Q FPLC and assayed as described in Materials and Methods. The
NaCl gradient is shown by the dotted line. The experiment was
repeated with essentially similar results.
Figure 7. ET-1 stimulation of HSP25/27 phosphorylation. Myo-
cytes were exposed to 100 nM ET-1 or 0.5 M sorbitol for the
times indicated. HSP25/27 phosphorylation was assessed by IEF
followed by immunoblotting as described in Materials and Meth-
ods. The anode is at the bottom of the figure. The blot is repre-
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cytes exposed to PE in the presence of PD98059 appeared
weakly stained and the myofilaments were not organized
(Fig. 11 D). In marked contrast to the results obtained up
to 24 h, myocytes exposed to PE in the presence of
SB203580 for 48 h were very small with minimal b-MHC
immunostaining and no myofibrillar organization (Fig. 11
E). Similar results were obtained with ET-1 (results not
shown). These data are not consistent with a role for the
p38-MAPK pathway in stimulating any of the morphologi-
cal changes induced by PE or ET-1. Rather, this pathway
may be important over a longer period in maintaining the
hypertrophic response. However, inhibition of the ERK
cascade by PD98059 clearly disrupts the myofibrillar orga-
nization induced by PE or ET-1.
Discussion
Activation of the p38-MAPK Pathway by
GPCR Agonists
The p38-MAPK cascade is activated in many cell types in
response to cellular stresses including hyperosmotic shock,
Figure 8. Morphological
changes induced by PE or
ET-1 in cardiac myocytes af-
ter 4 h. Myocytes were either
unstimulated (Control, A), or
exposed to 40 mM PE (B) or
40 nM ET-1 (C) for 4 h and
immunostained for b-MHC
as described in Materials and
Methods. Myocytes shown
are representative of a typical
field within a single experi-
ment. The experiment was re-
peated on three further occa-
sions with similar results. Bar,
25 mm.
Figure 9. Effects of PD98059
or SB203580 on the morpho-
logical changes induced by PE
or ET-1 in cardiac myocytes
after 8 h. (A–C) Myocytes
were either unstimulated
(Control,  A), or exposed to 40
mM PE (B) or 40 nM ET-1 (C)
for 8 h in the absence of inhibi-
tors. (D–F) Myocytes were
pretreated with 50 mM
PD98059 for 15 min and ex-
posed to 50 mM PD98059
alone (D), to PE in the pres-
ence of PD98059 (E), or to
ET-1 in the presence of
PD98059 (F) for 8 h. (G–I)
Myocytes were pretreated
with 10 mM SB203580 for 15
min and exposed to 10 mM
SB203580 alone (G), to PE in
the presence of SB203580 (H),
or to ET-1 in the presence of
SB203580 (I) for 8 h. Myo-
cytes were subsequently im-
munostained for b-MHC as
described in Materials and
Methods. Myocytes shown
are representative of a typical
field within a single experi-
ment. The experiment was re-
peated on five further occa-
sions with similar results. Bar,
25 mm.Clerk et al. The p38-MAPK Pathway Is Activated by GPCR Agonists 531
UV irradiation and exposure to proinflammatory cyto-
kines (reviewed by Kyriakis and Avruch, 1996a, 1996b;
Lee and Young, 1996; Cohen, 1997). There are very few
reports of activation of the p38-MAPK pathway by GPCR
agonists. p38-MAPK is activated in platelets by thrombin
(Kramer et al., 1995) and mediates thrombin stimulation
of phospholipase A2 activity (Kramer et al., 1996). The
chemotactic peptide N-formyl-Met-Leu-Phe also activates
p38-MAPK and MAPKAPK2 in neutrophils (Krump et
al., 1997). Cotransfection of m1 and m2 muscarinic acetyl-
choline receptors with an epitope-tagged p38-MAPK has
shown that these receptors can activate the pathway
(Yamauchi et al., 1997), but since the activation was only
approximately twofold, it is difficult to assess its signifi-
cance. A twofold activation of epitope-tagged p38-MAPK
is also seen after b-adrenergic stimulation (Yamauchi et
al., 1997). In similar experiments, transfection of a modi-
fied ETB receptor activates ERKs, SAPKs/JNKs and p38-
MAPKs (Aquilla et al., 1996). In a limited study, PE has
been shown to increase the phosphorylation of p38-
MAPK twofold in cardiac myocytes after 30 min (Zechner
et al., 1997), but this was not studied in detail and the acti-
vation of downstream events was not studied. We have
previously demonstrated that p38-MAPK is activated in
the perfused rat heart by pathophysiological stresses
(ischaemia and ischaemia/reperfusion [Bogoyevitch et al.,
1996], reactive oxygen species [Clerk et al., 1998] and hy-
pertensive perfusion [Clerk et al., 1998]).
In this study, we have clearly demonstrated that, in addi-
tion to cellular stress (hyperosmotic shock), the GPCR ag-
onists ET-1 and PE activate the p38-MAPK pathway in
primary cultures of neonatal rat ventricular myocytes.
Both agonists induced an z12-fold increase in the phos-
phorylation (activation) of p38-MAPK (Fig. 2) and a four-
to fivefold increase in the activity of the p38-MAPK sub-
strate, MAPKAPK2 (Fig. 4). This represents a significant
activation of the pathway and is z50% of the response
induced by a severe cellular stress, 0.5 M sorbitol (Figs. 2
and 4). The phosphorylation motif is similar in all the
p38-MAPKs and the antibody to the dually phosphory-
lated form recognizes all isoforms. Thus, from these exper-
iments, it is not possible to determine whether any specific
p38-MAPK isoforms were activated by the different
agonists. However, activation of MAPKAPK2 was com-
pletely inhibited by SB203580, which strongly inhibits p38-
MAPK(a) and p38-MAPKb1 and is a moderate inhibitor
of p38-MAPKb2 (Kumar et al., 1997), indicating that at
least one of these isoforms is activated in cardiac myo-
cytes. Furthermore, although p38-MAPK(a) is easily de-
tected on immunoblots of myocyte extracts, we have yet to
detect any of the other isoforms (Clerk, A., and P.H. Sug-
den, unpublished data).
From the results presented here, it is now apparent that
ET-1 and PE can activate all three of the best-character-
ized MAPK cascades in the heart. The ERK cascade was
first shown to be strongly activated by ET-1 (Bogoyevitch
Figure 10. Effects of PD98059
or SB203580 on the morpho-
logical changes induced by
PE or ET-1 in cardiac myo-
cytes after 24 h. (A–C) Myo-
cytes were either unstimu-
lated (Control, A), or exposed
to 40 mM PE (B) or 40 nM
ET-1 (C) for 24 h in the ab-
sence of inhibitors. (D–F)
Myocytes were pretreated
with 50 mM PD98059 for 15
min and exposed to 50 mM
PD98059 alone (D), to PE in
the presence of PD98059 (E),
or to ET-1 in the presence of
PD98059 (F) for 24 h. (G–I)
Myocytes were pretreated
with 10 mM SB203580 for 15
min and exposed to 10 mM
SB203580 alone (G), to PE in
the presence of SB203580
(H), or to ET-1 in the pres-
ence of SB203580 (I) for 24 h.
Myocytes were subsequently
immunostained for b-MHC
as described in Materials and
Methods. Myocytes shown
are representative of a typical
field within a single experi-
ment. The experiment was re-
peated on three further occa-
sions with similar results. Bar,
25 mm.The Journal of Cell Biology, Volume 142, 1998 532
et al., 1993, 1994) and, to a lesser extent by PE (Clerk et al.,
1994). ET-1 was then demonstrated to activate the SAPKs/
JNKs (approximately fivefold) whereas PE induced only
an approximately twofold activation of this pathway
(Bogoyevitch et al., 1995a). This twofold activation of
SAPKs/JNKs by PE was subsequently confirmed by others
(Ramirez et al., 1997). In contrast to the ERKs and SAPKs/
JNKs, the activation of the p38-MAPK pathway by PE is
comparable to that by ET-1 (Figs. 2 and 4).
Mechanism of Activation of the p38-MAPK Pathway
by ET-1
The ETA receptor mediates most of the effects of ET-1 in
cardiac myocytes (reviewed by Sugden and Bogoyevitch,
1996). ET-1–stimulated phosphorylation of p38-MAPK was
inhibited by BQ123, a selective ETA receptor antagonist
(see Results), indicating that activation of both pathways
is mediated through the same receptor. Consistent with
this, the EC50 for p38-MAPK phosphorylation (0.49 nM,
Fig. 3) by ET-1 in cardiac myocytes is similar to that for
ERK activation (0.2 nM) (Bogoyevitch et al., 1993). Stud-
ies of COS cells transfected with ETB receptors have also
indicated that a single receptor subtype can stimulate acti-
vation of ERKs, SAPKs/JNKs, and p38-MAPKs (Aquilla
et al., 1996), although whether this is through a single G
protein subtype remains to be determined. In our study,
ET-1–stimulated phosphorylation of p38-MAPK and acti-
vation of MAPKAPK2 was not affected by pretreatment
with PTX (Fig. 5, A and C), indicating that activation of
this pathway in cardiac myocytes is not mediated through
Gi/Go. We have previously shown that PTX inhibits ET-
1–induced activation of Raf (Bogoyevitch et al., 1995c),
the MKK kinase for the ERK cascade (reviewed by Sug-
den and Clerk, 1997). This suggests that activation of the
ERK and p38-MAPK pathways by ET-1 require activa-
tion of different G proteins. As expected, the activation of
the p38-MAPK pathway by 0.5 M sorbitol was unaffected
by PTX pretreatment (Fig. 5, B and D).
Phosphorylation of p38-MAPK and activation of
MAPKAPK2 by ET-1 appeared to be dependent on
PMA-sensitive isoforms of PKC since downregulation
of these isoforms or inhibition of PKC activity with
GF109203X significantly attenuated this response (Fig. 5,
A and C). This PKC-dependency was comparable to that
of ERK, which is also inhibited by PKC downregulation
(Bogoyevitch et al., 1994) and is inhibited by similar con-
centrations of GF109203X (Fig. 6 B). Activation of the
p38-MAPK pathway by hyperosmotic shock (0.5 M sorbi-
tol) was unaffected by either of these treatments (Fig. 5, B
and D), indicating that the data do not reflect a nonspe-
cific inhibitory effect of either PMA pretreatment or of
GF109203X on the p38-MAPK pathway. Although the ac-
tivation of p38-MAPK appears to be PKC-dependent,
PMA activation of PKC only stimulated approximately a
threefold increase in p38-MAPK phosphorylation and in
MAPKAPK2 activity. These data suggest that although
activation of the p38-MAPK pathway by ET-1 may be
PKC-dependent, other factors are necessary for full acti-
vation. Activation of PKC is mediated through Gq-stimu-
lation of phospholipase Cb (reviewed in Fields and Casey,
1997; Sugden and Clerk, 1997), suggesting that the ERK
and p38-MAPK pathways require Gq for full activation by
ET-1.
MAPKAPK2 is phosphorylated on multiple Ser/Thr
residues and these phosphorylations regulate its activity
(Ben-Levy et al., 1995). Although MAPKAPK2 is now
generally accepted to be a substrate for p38-MAPK
Figure 11. Effects of PD98059 or SB203580 on the morphological
changes induced by PE in cardiac myocytes after 48 h. (A–C)
Myocytes were unstimulated (Control, A), or exposed to 40 mM
PE (B and C) for 48 h in the absence of inhibitors. (D and E)
Myocytes were pretreated with 50 mM PD98059 (D) or 10 mM
SB203580 (E) for 15 min and exposed to PE in the presence of in-
hibitors for 48 h. Myocytes were subsequently immunostained for
b-MHC as described in Materials and Methods. Myocytes shown
are representative of a typical field within a single experiment.
The experiment was repeated on two further occasions with simi-
lar results. Bar, 25 mm.Clerk et al. The p38-MAPK Pathway Is Activated by GPCR Agonists 533
(Rouse et al., 1994; Ben-Levy et al., 1995), it was originally
identified as an ERK substrate (Stokoe et al., 1992) and at
least one site (Thr25) may be preferentially phosphorylated
by ERKs (Ben-Levy et al., 1995). Whereas phosphor-
ylation of Thr25 does not activate MAPKAPK2 on its own,
it may modulate the activation by the other phosphor-
ylation sites (Ben-Levy et al., 1995). PD98059 is a selective
inhibitor for MEK1 and, to a lesser extent, MEK2 (Alessi
et al., 1995; Dudley et al., 1995), although we are unaware
of any testing of PD98059 against other MKKs. PD98059
(50 mM) partially inhibited the activation of MAPKAPK2
by ET-1 (Fig. 5 C), but also partially inhibited p38-MAPK
phosphorylation (Fig. 5 A). At this concentration of
PD98059, activation of ERKs by ET-1 was essentially
completely inhibited and a lower concentration (10 mM),
which did not significantly inhibit MAPKAPK2 activation
(results not shown), almost completely inhibited ERK ac-
tivation (Fig. 6 C). These data indicate that ERK activa-
tion by ET-1 does not contribute to the activation of
MAPKAPK2, and provide circumstantial evidence that
PD98059 inhibits the activation of the MKK(s) of the
p38-MAPK pathway. In addition, we have shown that
SB203580 does not inhibit ERK activity (Fig. 4 C), but
completely abolishes the activation of MAPKAPK2 by
all agonists studied (Fig. 4 B). Although SB203580 does
inhibit some isoforms of SAPKs/JNKs in cardiac myo-
cytes (Clerk and Sugden, 1998), there is no evidence cur-
rently that these MAPKs phosphorylate and activate
MAPKAPK2. Therefore, the data are consistent with
phosphorylation of MAPKAPK2 by p38-MAPK being es-
sential for activation.
Role of p38-MAPKs in Hypertrophy or Cell Survival?
p38-MAPKs have been implicated in the development of
the hypertrophic phenotype in primary cultures of ventric-
ular myocytes. Transfection of constitutively activated
MKK6 (Zechner et al., 1997; Wang et al., 1998) or MKK3
(Wang et al., 1998) induces transcriptional and morpho-
logical changes associated with the hypertrophic response,
indicating that activation of the p38-MAPK pathway has
the potential to promote hypertrophy. However, the situa-
tion may be more complex as cotransfection of either
MKK3 or MKK6 with p38-MAPK(a) or p38-MAPKb sug-
gest that p38-MAPK(a) promotes apoptosis, whereas p38-
MAPKb induces hypertrophy (Wang et al., 1998). Such
transfection experiments are not unequivocal since (a)
there may be cross-talk between the MAPK pathways, and
(b) whereas activation of a single (overexpressed) path-
way may induce a particular response, the physiological
relevance of such a response cannot be assessed. Further-
more, in these studies, the myocytes are cultured in serum-
free conditions for up to 70 h before analysis. Beyond 24 h,
as discussed below, it becomes questionable whether stud-
ies of this nature are studies of hypertrophy or of myocyte
survival.
The hypertrophic response induced by a 48 h exposure
to PE is inhibited by SB203580 (Zechner et al., 1997).
Here, we have shown that the morphological changes as-
sociated with cardiac myocyte hypertrophy induced by
ET-1 or PE were apparent from as early as 4 h after stimu-
lation (Fig. 8, B and C), and that between 8 h (Fig. 9, B
and C) and 24 h (Fig. 10, B and C), the cells exhibited the
mature hypertrophic phenotype. We also demonstrated
that SB203580 had no effect on myocyte morphology over
this time period (Fig. 9, G–I and 10, G–I), strongly indicat-
ing that the p38-MAPK pathway is not necessary for the
induction of the morphological changes associated with
cardiac hypertrophy. After 48 h, myocytes exposed to PE
(Fig. 11, B and C) or ET-1 (results not shown) maintained
their myofibrillar organization and cell profile. However,
myocytes exposed to PE or ET-1 in the presence of
SB203580 were small, with minimal b-MHC staining and
no myofibrillar organization (Fig. 11 E and results not
shown). These data at 48 h are essentially similar to those
of Zechner et al. (1997) who only studied the effects at this
time point, but in view of the absence of any effect of this
inhibitor up to 24 h, suggest that the p38-MAPK pathway
may be necessary to maintain the cells during hypertrophy
rather than have a direct effect in stimulating the hy-
pertrophic response. Consistent with a role for the
p38-MAPK pathway in cytoprotection, activation of
MAPKAPK2 by ET-1 induced the sustained phosphoryla-
tion of HSP25/27 (Fig. 7). Such phosphorylation of HSP25/
27 is associated with cytoprotection in other cell types, and
is particularly important in the maintenance of the actin
cytoskeleton. Even though the activation of the p38-
MAPK pathway by ET-1 was only z50% of that by 0.5 M
sorbitol (Figs. 2 and 4), the extent of phosphorylation of
HSP25/27 induced by either agonist was similar (Fig. 7)
and may confer equivalent degrees of cytoprotection. Ex-
periments by others have implicated the p38-MAPK path-
way in ischemic preconditioning of the heart, whereby a
short period of ischemia protects the heart against a subse-
quent more prolonged insult (reviewed by Sumeray and
Yellon, 1997). Perfusion with SB203580 attenuates this
preconditioning (Weinbrenner et al., 1997) suggesting that
p38-MAPK, which is activated during ischemia (Bogo-
yevitch et al., 1996; Yin et al., 1997) plays an essential role
in the preconditioning response. Ischemic preconditioning
can be mimicked by perfusion with a1-adrenergic agonists
(Banerjee et al., 1993), ET-1 (Wang et al., 1996), and in
the rat heart, activation of PKC may be involved
(Speechly-Dick et al., 1994; Li and Kloner, 1995; Mitchell
et al., 1995). Our results are entirely consistent with a role
for p38-MAPK in ischemic preconditioning. Moreover,
since activation of the p38-MAPK pathway by GPCR ago-
nists in cardiac myocytes is attenuated by inhibition of
PKC, these data could explain the apparently disparate re-
sults implicating both PKC and p38-MAPK in ischemic
preconditioning.
The Role of the MAPKs in Cardiac Hypertrophy
The ERKs, SAPKs/JNKs, and p38-MAPKs have all been
implicated in cardiac hypertrophy, although the exact
roles of each of these pathways has yet to be determined.
Activation of the ERK cascade by transfection of myo-
cytes with constitutively activated components of the path-
way is not sufficient to induce the myofibrillar organiza-
tion associated with hypertrophy (Thorburn et al., 1994a,
b; Gillespie-Brown et al., 1995). However, in this study, we
have shown that PD98059, which inhibits the ERK path-
way and partially inhibits the p38-MAPK pathway, selec-The Journal of Cell Biology, Volume 142, 1998 534
tively inhibits the myofibrillar organization induced by PE
or ET-1 (Fig. 9, E and F), suggesting that the activation of
ERKs is essential for this response. However, it remains
possible that the effects of PD98059 may be mediated
through another, as yet unidentified mechanism. PD98059
does not inhibit the transcriptional changes associated
with PE-induced cardiac myocyte hypertrophy (Post et al.,
1996), although activation of the ERK cascade in transfec-
tion experiments can induce these changes (Gillespie-
Brown et al., 1995). Such apparently conflicting data are
probably indicative of the activation of multiple signaling
pathways by physiological agonists. For example, whilst
ERK activity may be necessary for myofibrillar organiza-
tion, other signaling pathways may be necessary for the
full response. Indeed, our data are fully supportive of hy-
pertrophy being an integrated response to multiple signal-
ing pathways, where ERKs may be involved in myofibril-
lar organization and p38-MAPK may be important in
potentiating the hypertrophic response. It remains proba-
ble that both (and other) pathways are necessary for the
full range of transcriptional and morphological changes as-
sociated with cardiac hypertrophy.
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